Contralateral neck failure in oral tongue cancer: Outcomes from two centers using predefined treatment criteria.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
07 2021
Historique:
revised: 14 12 2020
received: 22 08 2020
accepted: 26 02 2021
pubmed: 18 3 2021
medline: 2 7 2021
entrez: 17 3 2021
Statut: ppublish

Résumé

The objective was to determine the incidence of, and factors associated with contralateral neck failure (CNF) in oral tongue squamous cell carcinoma (OTSCC). Consecutive patients with OTSCC between 2007 and 2016 were included. The predefined policy of the contralateral neck included neck dissection (ND) where the primary tumor extended/crossed midline or the contralateral neck was involved; and elective nodal irradiation (ENI) where the primary tumor was ≤1 cm from midline/2 cm from tip. This study included 258 patients. ND was ipsilateral 169 (66%) and bilateral 33 (13%). Fifty-five patients (21%) received ENI to the undissected contralateral neck. CNF occurred in 19 patients (7%) and was similar by treatment received. Utilizing this approach, we observed higher rates of CNF with increasing N classification, perineural invasion, extracapsular extension, and depth of invasion ≥6 mm. Using our institutional policy of treatment to the contralateral neck, a low rate of CNF (≤10%) was observed.

Sections du résumé

BACKGROUND
The objective was to determine the incidence of, and factors associated with contralateral neck failure (CNF) in oral tongue squamous cell carcinoma (OTSCC).
METHODS
Consecutive patients with OTSCC between 2007 and 2016 were included. The predefined policy of the contralateral neck included neck dissection (ND) where the primary tumor extended/crossed midline or the contralateral neck was involved; and elective nodal irradiation (ENI) where the primary tumor was ≤1 cm from midline/2 cm from tip.
RESULTS
This study included 258 patients. ND was ipsilateral 169 (66%) and bilateral 33 (13%). Fifty-five patients (21%) received ENI to the undissected contralateral neck. CNF occurred in 19 patients (7%) and was similar by treatment received. Utilizing this approach, we observed higher rates of CNF with increasing N classification, perineural invasion, extracapsular extension, and depth of invasion ≥6 mm.
CONCLUSIONS
Using our institutional policy of treatment to the contralateral neck, a low rate of CNF (≤10%) was observed.

Identifiants

pubmed: 33729633
doi: 10.1002/hed.26671
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2024-2031

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Yamada K, Murakami M, Okamoto Y, et al. Treatment results of radiotherapy for carcinoma of the cervical esophagus. Acta Oncol. 2006;45(8):1120-1125.
Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 2008;112(2):345-351.
National Cancer Institute. Cancer Stat Facts: Tongue Cancer. https://seer.cancer.gov/statfacts/html/tongue.html. Accessed August 3, 2020.
D'Cruz AK, Vaish R, Kapre N, et al. Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med. 2015;373(6):521-529.
National Comprehensive Cancer Network. Head and Neck Cancers (Verson 2.2020). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed August 3, 2020.
Schilling C, Stoeckli SJ, Haerle SK, et al. Sentinel European node trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer. 2015;51(18):2777-2284.
Koo BS, Lim YC, Lee JS, Choi EC. Management of contralateral N0 neck in oral cavity squamous cell carcinoma. Head Neck. 2006;28(10):896-901.
Ganly I, Goldstein D, Carlson DL, et al. Long-term regional control and survival in patients with “low-risk,” early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness. Cancer. 2013;119(6):1168-1176.
Habib M, Murgasen J, Gao K, et al. Contralateral neck failure in lateralized oral squamous cell carcinoma. ANZ J Surg. 2016;86(3):188-192.
Kowalski LP, Bagietto R, Lara JR, Santos RL, Tagawa EK, Santos IR. Factors influencing contralateral lymph node metastasis from oral carcinoma. Head Neck. 1999;21(2):104-110.
Lim YC, Lee JS, Koo BS, Kim SH, Kim YH, Choi EC. Treatment of contralateral N0 neck in early squamous cell carcinoma of the oral tongue: elective neck dissection versus observation. Laryngoscope. 2006;116(3):461-465.
Koyfman SA, Ismaila N, Holsinger FC. Management of the neck in squamous cell carcinoma of the oral cavity and oropharynx: ASCO clinical practice guideline summary. J Oncol Pract. 2019;15(5):273-278.
Chin RI, Rao YJ, Hwang MY, et al. Comparison of unilateral versus bilateral intensity-modulated radiotherapy for surgically treated squamous cell carcinoma of the palatine tonsil. Cancer. 2017;123(23):4594-4607.
Amarasena I, Herschtal A, D'Costa I, et al. Outcomes of routine intensity modulated radiation therapy quality assurance in a large head and neck cancer center. Int J Radiat Oncol Biol Phys. 2017;98(3):541-546.
Edge SB, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. Seventh Edition. Chicago, IL: American Joint Committee on Cancer, Springer; 2011.
R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.
Liao CT, Chang JT, Wang HM, et al. Survival in squamous cell carcinoma of the oral cavity: differences between pT4 N0 and other stage IVA categories. Cancer. 2007;110(3):564-571.
Chan AK, Huang SH, Le LW, et al. Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure. Oral Oncol. 2013;49(3):255-260.
Farquhar DR, Masood MM, Lenze NR, et al. Academic affiliation and surgical volume predict survival in head and neck cancer patients receiving surgery. Laryngoscope. 2020;13(2):E479-E488. https://doi.org/10.1002/lary.28744.
Torabi SJ, Benchetrit L, Kuo Yu P, et al. Prognostic case volume thresholds in patients with head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2019;145:708.
Peters LJ, O'Sullivan B, Giralt J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 2010;28(18):2996-3001.
O'Steen L, Amdur RJ, Morris CG, Hitchcock KE, Mendenhall WM. Challenging the requirement to treat the contralateral neck in cases with >4 mm tumor thickness in patients receiving postoperative radiation therapy for squamous cell carcinoma of the oral tongue or floor of mouth. Am J Clin Oncol. 2019;42(1):89-91.
Brennan S, Corry J, Kleid S, et al. Prospective trial to evaluate staged neck dissection or elective neck radiotherapy in patients with CT-staged T1-2 N0 squamous cell carcinoma of the oral tongue. Head Neck. 2010;32(2):191-198.
Satgunaseelan L, Allanson BM, Asher R, et al. The incidence of squamous cell carcinoma of the oral tongue is rising in young non-smoking women: an international multi-institutional analysis. Oral Oncol. 2020;110:104875.
Ebrahimi A, Gil Z, Amit M, et al. Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study. JAMA Otolaryngol Head Neck Surg. 2014;140(12):1138-1148.
Amin MB, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. Eight Edition. Chicago, IL: American Joint Committee on Cancer, Springer; 2017.

Auteurs

Cristian Udovicich (C)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.

James Daniell (J)

Head and Neck Tumour Stream, Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

David Wiesenfeld (D)

Head and Neck Tumour Stream, Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

Mathias Bressel (M)

Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

David Rowe (D)

Head and Neck Tumour Stream, Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

Domenic Vital (D)

Head and Neck Tumour Stream, Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

Karda Cavanagh (K)

Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Ernest Lekgabe (E)

Department of Radiology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Tim Wong (T)

Head and Neck Tumour Stream, Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

Matthew J R Magarey (MJR)

Division of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Department of Medical Education, The University of Melbourne, Melbourne, Victoria, Australia.

Tim A Iseli (TA)

Head and Neck Tumour Stream, Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.

Tsien Fua (T)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.

Danny Rischin (D)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Lachlan McDowell (L)

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH